Cullinan Therapeutics Initiated Zipalertinib Drug Application
The firm began an FDA submission for a combination therapy to treat non-small cell lung cancer.
Updated on Oct. 2, 2026 in Cancer
Live Poll
Should the FDA continue to utilize accelerated review programs for new cancer drug applications?
Cullinan Therapeutics has initiated a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with chemotherapy. The application targets the treatment of previously untreated locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations.
Why it matters
This combination therapy aims to improve treatment outcomes for patients with specific genetic mutations that often complicate lung cancer care. The filing utilizes the FDA Real-Time Oncology Review program, which is designed to expedite the assessment of oncology drugs by reviewing clinical data early.
The REZILIENT3 trial met its primary endpoint, demonstrating improved median progression-free survival versus chemotherapy alone. Cullinan Therapeutics is eligible for $30 million and $100 million milestone payments upon specific regulatory approvals.
The players
Cullinan Therapeutics
A biopharmaceutical company based in Cambridge, Massachusetts, focused on developing targeted therapies for cancer.
Food and Drug Administration
The federal agency responsible for protecting public health by regulating the safety and efficacy of medical products in the United States.
The details
The submission is based on positive results from the Phase 3 REZILIENT3 trial, which compared the combination therapy to traditional chemotherapy. Zipalertinib has previously secured FDA Breakthrough Therapy designation for patients who have already undergone treatment.
Timeline
October 1, 2026: Cullinan Therapeutics initiated the NDA submission.
Year-end 2026: The company expects to complete the NDA submission.
February 27, 2027: The FDA has a PDUFA target action date for the separate monotherapy NDA.
The Big Picture
The use of the FDA Real-Time Oncology Review program marks a departure from traditional, slower drug approval cycles. This approach follows the pattern set by the agency to accelerate the delivery of oncology treatments by reviewing trial data as they become available.
The potential approval of this combination therapy offers a new treatment option for patients diagnosed with locally advanced or metastatic non-small cell lung cancer. These developments represent a shift toward addressing specific genetic mutations that were previously more difficult to manage.
The takeaway
Patients diagnosed with lung cancer should consult with their oncologists to determine if their condition involves specific genetic markers like EGFR exon 20 insertions. Understanding these mutations is increasingly vital for identifying eligible clinical trials and emerging targeted therapies.
Further reading
For more information on the current state of lung cancer research, explore the Cancer section.
Live Poll
Should the FDA continue to utilize accelerated review programs for new cancer drug applications?
